lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Scientific literature indicates that some of the compounds of bismuth are less toxic to humans via ingestion than other heavy metals (lead, arsenic, antimony, etc.) presumably due to the comparatively low solubility of bismuth salts. Its biological half-life for whole-body retention is reported to be 5 days, but it can remain in the kidney for years in people treated with bismuth compounds. Bismuth poisoning can occur and has, according to some reports, been common in relatively recent times. As with lead, bismuth poisoning can result in the formation of a black deposit on the gingiva, known as a bismuth line. Poisoning may be treated with dimercaprol, but evidence for benefit is unclear. Bismuth's environmental impacts are not well known; it may be less likely to bioaccumulate than some other heavy metals, and this is an area of active research.
Metiussl is eventually deleted by Deka Master while Cannon Gladiator is eaten by Gigas, which is subsequently destroyed by Deka Base Robo. Metiussl is voiced by Hisanori Koyatsu (小谷津 央典, Koyatsu Hisanori). Ozchuian Ial (オズチュウ星人イーアル, Ozuchū Seijin Īaru): A kung fu/Drunken Master–themed criminal from Planet Ozchu who is charged with medical violations and homicide, can strengthen himself by drinking alcohol, carries a bottle of Earth sake, and possesses a fighting style tailored to how drunk he is. He poses as a restaurateur named Wang (ワン, Wan) until he is confronted by Umeko, enlarges himself, and is deleted by Dekaranger Robo. Ial is voiced by Dandy Sakano (ダンディ坂野, Dandi Sakano), who also portrays Wang. Woojonian Jinche (ウージョン星人ジンチェ, Wūjon Seijin Jinche): A criminal from Planet Woojon who possesses the ability to swap bodies with another and is wanted on seven planets on burglary and vandalism charges. After being captured by S.P.D. while using a Kaijuki called Shinobi Shadow 2 (シノビシャドー2, Shinobi Shadō Tsū), which was destroyed by Deka Base Robo, he attempts to take over the Deka Base for himself and reveal its secrets to Agent Abrella by switching bodies with Hoji, only to partially succeed in the latter task before he is returned to his original body and deleted by the Dekarangers via the D-Bazooka. Jinche is voiced by Yukitoshi Hori (堀 之紀, Hori Yukitoshi). Guermerlian Byz Goa (ゲルマー星人バイズ・ゴア, Gerumā Seijin Baizu Goa): A tiny planetary bomber and destroyer of worlds, from Planet Geurmerl.
The André E. Lalonde Accelerator Mass Spectrometry Laboratory is an accelerator mass spectrometry research facility at the University of Ottawa in Canada. It is currently the only facility of its type in Canada. It is named after former University of Ottawa Faculty of Science dean André E. Lalonde, who died in 2012.
Sources: en.wikipedia.org
=== Spraying === Spray painting High velocity oxygen fuel (HVOF) Plasma spraying Thermal spraying Kinetic metallization (KM) Plasma transferred wire arc thermal spraying The common forms of Powder coating
=== Recurring === Kaitlin Olson as Deborah "DJ" Vance Jr., Deborah's daughter who sells personal crafts Chris McDonald as Marty Ghilain, CEO of the Palmetto Casino Paul W. Downs as Jimmy LuSaque Jr., Deborah and Ava's manager Rose Abdoo as Josefina, Deborah's house manager Lorenza Izzo as Ruby, Ava's ex-girlfriend and an actress Megan Stalter as Kayla Schaeffer, Jimmy's inept assistant and boss's daughter Mark Indelicato as Damien, Deborah's personal assistant Poppy Liu as Kiki, Deborah's personal blackjack dealer and an employee at the Palmetto Johnny Sibilly as Wilson, a Vegas public water inspector and Marcus' love interest Angela E. Gibbs as Robin, Marcus' mother Jane Adams as Nina Daniels, Ava's mother Louis Herthum as Dennis Daniels, Ava's father who is recovering from a stroke Amanda Payton as Jackie, one of DJ's friends Joe Mande as Ray, a front desk clerk at the Palmetto Danielle Schneider as Rina, Marty's assistant Lauren Weedman as Jo Pezzimenti, the mayor of Las Vegas
=== Books === Holick, MF (2011). The Vitamin D Solution: A 3-Step Strategy to Cure Our Most Common Health Problems. Plume 1st edition. ISBN 978-0452296886. Holick, MF; Dawson-Hughes, B (2010) [2004]. Nutrition and Bone Health. Humana Press. ISBN 978-1617374517. Holick, MF, ed. (2010). Vitamin D: Physiology, Molecular Biology, and Clinical Applications (2nd ed.). Humana Press. ISBN 978-1603273008. Holick, MF; Jenkins, Mark (2005). UV Advantage (2nd ed.). IBOOKS. ISBN 978-1596879003.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.